UK HAIs (hospital acquired infection): a £1 billion challenge
This article was originally published in Clinica
This week saw a spate of reports on the UK's hospital acquired infection (HAI) situation. The problem - which already costs the NHS an estimated £1bn ($1.86bn) a year - is being billed as the UK's greatest healthcare challenge, affecting over 100,000 patients and causing some 5,000 deaths. These 2000 figures are said to be "the best estimate available", according to the National Audit Office, in its four-year review of the situation. The NAO report criticises the failure to establish a comprehensive mandatory surveillance scheme, despite plans to improve HAI monitoring (through the NINSS set up in 1996) with orthopaedic surgical site infection, bacteraemia and post-discharge surveillance.
You may also be interested in...
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.
Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment.